This 2023 Recommendation Statement from the US Preventive Services Task Force recommends screening for LTBI in populations at increased risk (B recommendation).
This 2023 Recommendation Statement from the US Preventive Services Task Force concludes that the current evidence is insufficient to assess the balance of benef
This 2023 Recommendation Statement from the US Preventive Services Task Force recommends against routine serologic screening for genital HSV infection in asympt
This 2022 Recommendation Statement from the US Preventive Services Task Force concludes that the current evidence is insufficient to assess the balance of benef
This 2022 Recommendation Statement from the US Preventive Services Task Force recommends against the use of combined estrogen and progestin for the primary prev